CoLucid

News
brain

Lilly buys pain biotech CoLucid for $960m

Eli Lilly’s new chief executive David Ricks has made his first acquisition, bringing in biotech CoLucid for $960 million – reacquiring a migraine drug the big pharma sold off 12 years ago.<